Key result
Succinobucol attenuates platelet aggregation and reverses oxidant stress-induced increases in rabbit and rat blood.
Why the study?
The study aimed to determine if the antioxidant activity of succinobucol is responsible for its antiplatelet effects given the role of oxidant stress in platelet interactions.
Does succinobucol reduce platelet aggregation and reverse oxidant stress effects in preclinical models?
Does succinobucol reduce platelet aggregation and reverse oxidant stress effects in preclinical models?
Succinobucol exhibits significant antiplatelet activity and reverses oxidant stress-induced platelet aggregation in preclinical models.
Answers are grounded in this paper and cite their sources.
Succinobucol attenuates oxidant-driven platelet aggregation in rabbit and rat models; leaves open any human antiplatelet role.
Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Given the importance of oxidant stress in modulating platelet–platelet and platelet–vessel wall interactions, the aim of this study was to establish if antioxidant activity was responsible for the antiplatelet activity of succinobucol. Platelet aggregation in response to collagen and adenosine diphosphate (ADP) was studied in rabbit whole blood and platelet-rich plasma using impedance aggregometry. The effect of oxidant stress on aggregation, platelet lipid peroxides, and vascular tone was studied by incubating platelets, washed platelets or preconstricted rabbit iliac artery rings respectively with a combination of xanthine and xanthine oxidase (X/XO). To study the effect of succinobucol in vivo, anaesthetized rats were injected with up to 150 mg/kg succinobucol and aggregation measured in blood removed 15 mins later. Succinobucol (10−5–10−4 M) significantly attenuated platelet aggregation to collagen and ADP in whole blood and platelet-rich plasma. X/XO significantly increased aggregation to collagen and platelet lipid peroxides and this was reversed by succinobucol. Addition of X/XO to denuded rabbit iliac arteries caused a dose-dependent relaxation which was significantly inhibited by succinobucol. In vivo administration up to 150 mg/kg had no effect on heart rate or mean arterial blood pressure but significantly inhibited platelet aggregation to collagen ex vivo. In conclusion, succinobucol displays anti-platelet activity in rabbit and rat blood and reverses the increase in platelet aggregation in response to oxidant stress.
No takes yet. Share an insight, caveat, or question.
Houston et al. (2016) studied this question. Succinobucol (AGI-1067) was evaluated on Platelet aggregation to collagen and ADP. Succinobucol significantly attenuated platelet aggregation to collagen and ADP in rabbit and rat blood and reversed the increase in platelet aggregation in response to oxidant stress.
Synapse has enriched 10 related papers. Consider them for comparative context: